| Dr Stephanie Kay Denison, MD | |
|
5323 Harry Hines Blvd, Dallas, TX 75390-7201 | |
| (214) 590-8000 | |
| Not Available |
| Full Name | Dr Stephanie Kay Denison |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 5323 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033566476 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Mansfield Medical Center | Mansfield, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Physician Resources, Llp | 7012161375 | 74 |
News Archive
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
At least one in ten adults over the age of 65 suffers from Mild Cognitive Impairment, or MCI. This condition, a state between the normal decline in cognition associated with aging and the more precipitous drop caused by a deadly dementia like Alzheimer's disease, has only recently begun to be studied; first identified by the Mayo Clinic in 1999, it was only given an official diagnostic code in late 2006.
Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.
The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.
› Verified 2 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
At least one in ten adults over the age of 65 suffers from Mild Cognitive Impairment, or MCI. This condition, a state between the normal decline in cognition associated with aging and the more precipitous drop caused by a deadly dementia like Alzheimer's disease, has only recently begun to be studied; first identified by the Mayo Clinic in 1999, it was only given an official diagnostic code in late 2006.
Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.
The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.
› Verified 2 days ago
| Entity Name | Texas Physician Resources, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639413289 PECOS PAC ID: 7012161375 Enrollment ID: O20130214000159 |
News Archive
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
At least one in ten adults over the age of 65 suffers from Mild Cognitive Impairment, or MCI. This condition, a state between the normal decline in cognition associated with aging and the more precipitous drop caused by a deadly dementia like Alzheimer's disease, has only recently begun to be studied; first identified by the Mayo Clinic in 1999, it was only given an official diagnostic code in late 2006.
Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.
The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.
› Verified 2 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
At least one in ten adults over the age of 65 suffers from Mild Cognitive Impairment, or MCI. This condition, a state between the normal decline in cognition associated with aging and the more precipitous drop caused by a deadly dementia like Alzheimer's disease, has only recently begun to be studied; first identified by the Mayo Clinic in 1999, it was only given an official diagnostic code in late 2006.
Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.
The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephanie Kay Denison, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: () - | Dr Stephanie Kay Denison, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: (214) 590-8000 |
News Archive
The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).
At least one in ten adults over the age of 65 suffers from Mild Cognitive Impairment, or MCI. This condition, a state between the normal decline in cognition associated with aging and the more precipitous drop caused by a deadly dementia like Alzheimer's disease, has only recently begun to be studied; first identified by the Mayo Clinic in 1999, it was only given an official diagnostic code in late 2006.
Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.
The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.
› Verified 2 days ago
Bradford Stager Commons, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235 Phone: 214-590-8058 | |
Dr. Sandeep Guttikonda, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-648-3916 Fax: 214-648-8423 | |
Jeffrey Szot, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7777 Forest Ln, Dallas, TX 75230 Phone: 972-566-2667 | |
Matthew Tice, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12221 Merit Dr, Suite 1500, Dallas, TX 75251 Phone: 214-217-1911 | |
Dr. Renjie Michael Li, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13737 Noel Rd, Dallas, TX 75240 Phone: 214-217-1912 | |
James Pierre D'etienne, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Gaston Ave, Dallas, TX 75246 Phone: 214-820-2505 Fax: 214-712-2487 | |
Aditya Lulla, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6201 Harry Hines Blvd, Dallas, TX 75235 Phone: 214-633-5555 |